Rogers M J, Law L W, Appella E, Oroszlan S, Ting C C
Int J Cancer. 1977 Aug 15;20(2):303-8. doi: 10.1002/ijc.2910200220.
Antigens present in gp70 and p30 purified from Rauscher virus, were tested for immunogenicity in various assays measuring the anti-tumor immune response against lymphocytic leukemias of Friend (FBL-3) or Rauscher (RBL-5) virus origin. p30 had no effect on in vitro cytotoxicity against tumor cell targets mediated by either an anti RBL-5 serum or lymphocytes from animals immunized with FBL-3 cells. gp70 had had no effect on serum-mediated cytotoxicity but used at high concentrations it inhibited cell-mediated cytotoxicity. When used to immunize mice directly against subsequent challenge with the RBL-5 and FBL-3 leukemias, p30 had no discernible effect, while gp70 afforded partial protection against RBL-5 but only at high concentrations. Cell-free preparations of tumor membranes containing negligible amounts of gp70 were antigenically superior to gp70 in both the in vitro and in vivo assays. It is concluded that antigens on these purified proteins that are also expressed on tumor cells are not major targets of the anti-tumor immune response in this system.
从劳氏病毒中纯化出的gp70和p30中的抗原,在各种检测抗Friend(FBL-3)或劳氏(RBL-5)病毒源性淋巴细胞白血病的抗肿瘤免疫反应的试验中,检测其免疫原性。p30对由抗RBL-5血清或用FBL-3细胞免疫的动物的淋巴细胞介导的针对肿瘤细胞靶标的体外细胞毒性没有影响。gp70对血清介导的细胞毒性没有影响,但在高浓度使用时会抑制细胞介导的细胞毒性。当直接用于免疫小鼠以抵抗随后的RBL-5和FBL-3白血病攻击时,p30没有明显效果,而gp70仅在高浓度时能提供对RBL-5的部分保护。在体外和体内试验中,含有可忽略不计的gp70量的肿瘤膜无细胞制剂在抗原性上优于gp70。得出的结论是,这些纯化蛋白上同时也在肿瘤细胞上表达的抗原不是该系统中抗肿瘤免疫反应的主要靶标。